{'fraction_non_alphanumeric': 0.020703933747412008, 'fraction_numerical': 0.037267080745341616, 'mean_word_length': 5.816901408450704, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Co‐administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population

The co‐administration of cytochrome P450 3A4 (CYP3A4) inhibitors with simvastatin or atorvastatin (CYP3A4‐metabolised statins) is associated with increased statin exposure and can increase the risk of adverse drug reactions. The aim of this study was to measure the concomitant exposure of patients to CYP3A4‐metabolised statins and CYP3A4 inhibitors in the UK primary care population.